Merck - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: Merck reported a 52 percent decline in second-quarter profit, as merger-related and restructuring costs more than offset a near doubling in sales as a result of its takeover of Schering-Plough. But without those one-time charges, profits actually grew, beating analysts' estimates. The company's biggest drug, Singulair, posted flat sales of $1.26 billion, while the newly-off-patent blood-pressure drugs Cozaar and Hyzaar saw revenues drop 46 percent to $485 million.

Highlights

  • Second-Quarter 2010 Non-GAAP EPS of $0.86, Excluding Certain Items; Second-Quarter GAAP EPS of $0.24
  • Key Pharmaceutical Products, Consumer Care and Animal Health Deliver Strong Performance
  • Merger Integration Achieving Strategic Intent; Synergy Target of $3.5 Billion of Annual Savings in 2012 Reaffirmed
  • Full-Year 2010 Non-GAAP EPS Range of $3.29 to $3.39, Excluding Certain Items; 2010 GAAP EPS Range of $0.82 to $1.16
  • Target of High Single-Digit Non-GAAP EPS Compound Annual Growth Rate from 2009 to 2013 Reaffirmed

See Merck's current stock quote from CNN Money

Merck's website: http://www.merck.com/
Full earnings release: Merck release

Merck - Big Pharma's Q2 2010 Earnings Report
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.